Other · developed by Verrica Pharmaceuticals
VP-315 is an agent administered by intratumor injection into a single target lesion, with dosing schedules of 2 to 8 mg daily over consecutive days. It is studied in basal cell carcinoma and other skin cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05188729 | Phase 2 | Basal Cell Carcinoma | Completed | VRCA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Basal Cell CarcinomaCancer of the SkinCancer of the Skin, Basal CellCarcinomaSkin Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the VRCA page.
See VRCA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VRCA catalysts and pipeline →